PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.

ABSTRACT:

Background

PD-L1 expression levels determined by immunostaining are known to be related to the survival rate and prognosis of patients with various types of cancers, as well as to the therapeutic response to immune checkpoint inhibitors. Recently, the U.S. Food and Drug Administration approved an immune checkpoint inhibitor for the treatment of non-small cell lung cancer along with the clones used for PD-L1 immunostaining to predict the resulting response. In this study, we performed PD-L1 immunostaining of tissue microarrays from ovarian epithelial cancer using SP263, an approved clone, and examined the effect of PD-L1 expression on survival rate and prognosis.

Methods

Tissue microarrays were constructed from ovarian epithelial cancer tissues of 248 patients and PD-L1 immun

SUBMITTER: Kim KH 

PROVIDER: S-EPMC6580633 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature